<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 获取免费报告) 董事 Hongbo Lu 于 5 月 12 日星期二出售了 2,970 股公司股票。股票以平均价格 $76.88 出售，总价值为 $228,333.60。交易后，该董事持有 52,012 股公司股票，估值约为 $3,998,682.56。这代表其持股减少了 5.40%。此次出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。</p>
<h2>Arrowhead Pharmaceuticals 股价上涨 2.3%</h2>
<ul>
<li>想要在生物技术领域获得多元化的上行潜力？查看 LABU</li>
</ul>
<p>ARWR 的股票在周四的交易时段上涨了 $1.81，达到 $79.69。该公司交易了 1,799,277 股，较其平均交易量 1,916,164 股有所减少。公司的 50 日移动平均价格为 $65.71，200 日移动平均价格为 $61.75。公司的速动比率为 6.23，流动比率为 6.23，债务与股本比率为 1.41。公司的市值为 112.3 亿美元，市盈率为 -37.06，贝塔值为 1.28。Arrowhead Pharmaceuticals, Inc. 的 12 个月低点为 $14.30，12 个月高点为 $82.26。</p>
<p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - 获取免费报告) 最近于 5 月 7 日星期四发布了季度财报。该生物技术公司报告本季度每股收益为 ($0.93)，超出市场共识预期的 ($1.10) $0.17。该公司本季度的收入为 $73.74 百万美元，而分析师预期为 $73.84 百万美元。Arrowhead Pharmaceuticals 的股本回报率为 -55.09%，净利润率为 -48.38%。该公司的收入同比下降了 86.4%。在去年同期，该公司每股收益为 $2.75。股票研究分析师预测 Arrowhead Pharmaceuticals, Inc. 本财年每股收益将为 -2.97。</p>
<h2>机构投资者对 Arrowhead Pharmaceuticals 的看法</h2>
<p>几家对冲基金和其他机构投资者最近对 ARWR 的持仓进行了调整。Siren L.L.C. 在第一季度将其在 Arrowhead Pharmaceuticals 的股份增加了 7.7%。Siren L.L.C. 目前持有 1,615,476 股该生物技术公司的股票，价值 $101,290,000，此前在上个季度购买了额外的 115,000 股。Inceptionr LLC 在第一季度购买了 Arrowhead Pharmaceuticals 的新股份，价值 $426,000。诺瓦斯科舍银行在第一季度购买了 Arrowhead Pharmaceuticals 的新股份，价值 $8,525,000。Cetera Investment Advisers 在第一季度将其在 Arrowhead Pharmaceuticals 的股份增加了 40.7%。Cetera Investment Advisers 目前持有 9,424 股该生物技术公司的股票，价值 $591,000，此前在上个季度购买了额外的 2,727 股。最后，WCM Investment Management LLC 在第一季度将其在 Arrowhead Pharmaceuticals 的持股增加了 23.5%。WCM Investment Management LLC 目前持有 171,575 股该生物技术公司的股票，估值为 $9,891,000，此前在此期间获得了额外的 32,670 股。对冲基金和其他机构投资者持有该公司 62.61% 的股份。</p>
<h2>分析师设定新的价格目标</h2>
<p>多家券商最近对 ARWR 发表了评论。Sanford C. Bernstein 将 Arrowhead Pharmaceuticals 的价格目标从 $35.00 上调至 $46.00，并在周三的研究报告中给予该股票 “市场表现” 评级。HC Wainwright 在 3 月 25 日的报告中重申了 “买入” 评级，并设定了 $100.00 的价格目标。B. Riley Financial 在 1 月 22 日的研究报告中将 Arrowhead Pharmaceuticals 的价格目标从 $61.00 上调至 $101.00，并给予该股票 “买入” 评级。摩根大通在 5 月 1 日的研究报告中开始覆盖 Arrowhead Pharmaceuticals 的股票。他们设定了 “增持” 评级和 $88.00 的价格目标。最后，加拿大皇家银行在 5 月 8 日的研究报告中将 Arrowhead Pharmaceuticals 的价格目标从 $80.00 上调至 $87.00，并给予该公司 “跑赢大盘” 评级。一位分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 $87.80。</p>
<p><strong>查看我们对 ARWR 的最新分析</strong></p>
<h2>更多 Arrowhead Pharmaceuticals 新闻</h2>
<p>以下是本周影响 Arrowhead Pharmaceuticals 的主要新闻故事：</p>
<ul>
<li>积极情绪：HC Wainwright 对 Arrowhead Pharmaceuticals 维持 <strong>买入</strong> 评级，并保持 <strong>$100 的目标价</strong>，同时上调了一些中长期的盈利预测，包括 FY2026 和 2026 年第四季度的预估。Arrowhead Pharmaceuticals 分析师估计更新</li>
<li>积极情绪：Sanford C. Bernstein 将其 <strong>目标价从 $35 上调至 $46</strong>，表明对 Arrowhead 前景的信心有所增强，尽管其评级仍为 <strong>市场表现</strong>。Bernstein 上调 Arrowhead 目标价</li>
<li>中性情绪：HC Wainwright 对几个季度的每股收益预估仅进行了小幅修订，有些季度略低，有些季度略高，表明 Arrowhead 的管线驱动盈利路径整体论点没有重大变化。HC Wainwright 估计修订</li>
<li>中性情绪：最近的报道还强调了 Arrowhead 正在进行的估值辩论和即将公布的临床结果，这可能在关键催化剂之前保持了投资者的兴趣。2026 年下半年多个重要临床结果</li>
<li>消极情绪：HC Wainwright 下调了 Arrowhead 的几个短期盈利预测，包括 2026 年第三季度、2027 年第一季度和 2027 年第二季度，这反映了对持续亏损的预期，直到最终改善。Arrowhead 短期盈利估计下调</li>
</ul>
<h2>关于 Arrowhead Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Arrowhead Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于 RNA 干扰 (RNAi) 治疗药物的发现、开发和商业化。自 2008 年成立以来，Arrowhead 利用其专有的递送平台——内部称为先进 RNAi 化合物 (ARC) 技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久的、针对性的治疗，涵盖多个治疗领域。</p>
<p>该公司的管线包括多个处于不同开发阶段的候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Arrowhead Pharmaceuticals</li>
<li>YETI 在盈利超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度盈利后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Arrowhead Pharmaceuticals 吗？</h2>
<p>在考虑 Arrowhead Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而 Arrowhead Pharmaceuticals 并不在名单上。</p>
<p>虽然 Arrowhead Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

箭头制药

标普全球医疗股指数 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>箭头制药董事卢洪波以每股 76.88 美元的价格出售了 2,970 股，总计 228,333.60 美元，减少了 5.40% 的持股比例。出售后，他持有 52,012 股，估值约为 399 万美元。该交易已向美国证券交易委员会（SEC）披露，并在 10b5-1 规则下执行。该股票最近上涨了 2.3%，交易价格为 79.69 美元，市值为 112.3 亿美元，上一季度每股收益为-0.93 美元</p>

<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Hongbo Lu sold 2,970 shares of the company's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director owned 52,012 shares of the company's stock, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 获取免费报告) 董事 Hongbo Lu 于 5 月 12 日星期二出售了 2,970 股公司股票。股票以平均价格 $76.88 出售，总价值为 $228,333.60。交易后，该董事持有 52,012 股公司股票，估值约为 $3,998,682.56。这代表其持股减少了 5.40%。此次出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。</p>
</div><h2>Arrowhead Pharmaceuticals Trading Up 2.3%</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 股价上涨 2.3%</h2>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上行潜力？查看 LABU</li>
</ul>
</div><p>Shares of ARWR traded up $1.81 during trading hours on Thursday, reaching $79.69. 1,799,277 shares of the company traded hands, compared to its average volume of 1,916,164. The company's fifty day moving average price is $65.71 and its two-hundred day moving average price is $61.75. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $11.23 billion, a price-to-earnings ratio of -37.06 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $82.26.</p>
<div class="lb-trans"><p>ARWR 的股票在周四的交易时段上涨了 $1.81，达到 $79.69。该公司交易了 1,799,277 股，较其平均交易量 1,916,164 股有所减少。公司的 50 日移动平均价格为 $65.71，200 日移动平均价格为 $61.75。公司的速动比率为 6.23，流动比率为 6.23，债务与股本比率为 1.41。公司的市值为 112.3 亿美元，市盈率为 -37.06，贝塔值为 1.28。Arrowhead Pharmaceuticals, Inc. 的 12 个月低点为 $14.30，12 个月高点为 $82.26。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm's revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 earnings per share. Equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.97 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - 获取免费报告) 最近于 5 月 7 日星期四发布了季度财报。该生物技术公司报告本季度每股收益为 ($0.93)，超出市场共识预期的 ($1.10) $0.17。该公司本季度的收入为 $73.74 百万美元，而分析师预期为 $73.84 百万美元。Arrowhead Pharmaceuticals 的股本回报率为 -55.09%，净利润率为 -48.38%。该公司的收入同比下降了 86.4%。在去年同期，该公司每股收益为 $2.75。股票研究分析师预测 Arrowhead Pharmaceuticals, Inc. 本财年每股收益将为 -2.97。</p>
</div><h2>Institutional Investors Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Arrowhead Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in ARWR. Siren L.L.C. increased its stake in shares of Arrowhead Pharmaceuticals by 7.7% in the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company's stock worth $101,290,000 after purchasing an additional 115,000 shares in the last quarter. Inceptionr LLC bought a new position in Arrowhead Pharmaceuticals in the 1st quarter worth $426,000. Bank of Nova Scotia purchased a new stake in Arrowhead Pharmaceuticals in the 1st quarter worth $8,525,000. Cetera Investment Advisers increased its stake in Arrowhead Pharmaceuticals by 40.7% in the 1st quarter. Cetera Investment Advisers now owns 9,424 shares of the biotechnology company's stock worth $591,000 after buying an additional 2,727 shares in the last quarter. Finally, WCM Investment Management LLC raised its holdings in Arrowhead Pharmaceuticals by 23.5% during the first quarter. WCM Investment Management LLC now owns 171,575 shares of the biotechnology company's stock valued at $9,891,000 after acquiring an additional 32,670 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 ARWR 的持仓进行了调整。Siren L.L.C. 在第一季度将其在 Arrowhead Pharmaceuticals 的股份增加了 7.7%。Siren L.L.C. 目前持有 1,615,476 股该生物技术公司的股票，价值 $101,290,000，此前在上个季度购买了额外的 115,000 股。Inceptionr LLC 在第一季度购买了 Arrowhead Pharmaceuticals 的新股份，价值 $426,000。诺瓦斯科舍银行在第一季度购买了 Arrowhead Pharmaceuticals 的新股份，价值 $8,525,000。Cetera Investment Advisers 在第一季度将其在 Arrowhead Pharmaceuticals 的股份增加了 40.7%。Cetera Investment Advisers 目前持有 9,424 股该生物技术公司的股票，价值 $591,000，此前在上个季度购买了额外的 2,727 股。最后，WCM Investment Management LLC 在第一季度将其在 Arrowhead Pharmaceuticals 的持股增加了 23.5%。WCM Investment Management LLC 目前持有 171,575 股该生物技术公司的股票，估值为 $9,891,000，此前在此期间获得了额外的 32,670 股。对冲基金和其他机构投资者持有该公司 62.61% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of brokerages have recently commented on ARWR. Sanford C. Bernstein boosted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a &#34;market perform&#34; rating in a research report on Wednesday. HC Wainwright restated a &#34;buy&#34; rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. B. Riley Financial upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, January 22nd. JPMorgan Chase &amp; Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an &#34;overweight&#34; rating and a $88.00 price objective on the stock. Finally, Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.80.</p>
<div class="lb-trans"><p>多家券商最近对 ARWR 发表了评论。Sanford C. Bernstein 将 Arrowhead Pharmaceuticals 的价格目标从 $35.00 上调至 $46.00，并在周三的研究报告中给予该股票 “市场表现” 评级。HC Wainwright 在 3 月 25 日的报告中重申了 “买入” 评级，并设定了 $100.00 的价格目标。B. Riley Financial 在 1 月 22 日的研究报告中将 Arrowhead Pharmaceuticals 的价格目标从 $61.00 上调至 $101.00，并给予该股票 “买入” 评级。摩根大通在 5 月 1 日的研究报告中开始覆盖 Arrowhead Pharmaceuticals 的股票。他们设定了 “增持” 评级和 $88.00 的价格目标。最后，加拿大皇家银行在 5 月 8 日的研究报告中将 Arrowhead Pharmaceuticals 的价格目标从 $80.00 上调至 $87.00，并给予该公司 “跑赢大盘” 评级。一位分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 $87.80。</p>
</div><p><strong>View Our Latest Analysis on ARWR</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ARWR 的最新分析</strong></p>
</div><h2>More Arrowhead Pharmaceuticals News</h2>
<div class="lb-trans"><h2>更多 Arrowhead Pharmaceuticals 新闻</h2>
</div><p>Here are the key news stories impacting Arrowhead Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响 Arrowhead Pharmaceuticals 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright kept a <strong>Buy</strong> rating on Arrowhead Pharmaceuticals and maintained a <strong>$100 price target</strong>, while also raising some medium- and longer-term earnings forecasts, including FY2026 and Q4 2026 estimates. Arrowhead Pharmaceuticals analyst estimate updates</li>
<li>Positive Sentiment: Sanford C. Bernstein raised its <strong>price target from $35 to $46</strong>, signaling improved confidence in Arrowhead’s outlook, even though its rating remains <strong>Market Perform</strong>. Bernstein raises Arrowhead price target</li>
<li>Neutral Sentiment: HC Wainwright made only small revisions to several quarterly EPS estimates, with some quarters slightly lower and others slightly higher, suggesting no major change in the overall thesis for Arrowhead’s pipeline-driven earnings path. HC Wainwright estimate revisions</li>
<li>Neutral Sentiment: Recent coverage also highlighted Arrowhead’s ongoing valuation debate and upcoming clinical readouts, which may be keeping investor interest elevated ahead of key catalysts. Multiple important clinical readouts in 2H26</li>
<li>Negative Sentiment: HC Wainwright trimmed several near-term earnings forecasts for Arrowhead, including Q3 2026, Q1 2027 and Q2 2027, which reflects expectations for continued losses before eventual improvement. Arrowhead near-term earnings estimate cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 对 Arrowhead Pharmaceuticals 维持 <strong>买入</strong> 评级，并保持 <strong>$100 的目标价</strong>，同时上调了一些中长期的盈利预测，包括 FY2026 和 2026 年第四季度的预估。Arrowhead Pharmaceuticals 分析师估计更新</li>
<li>积极情绪：Sanford C. Bernstein 将其 <strong>目标价从 $35 上调至 $46</strong>，表明对 Arrowhead 前景的信心有所增强，尽管其评级仍为 <strong>市场表现</strong>。Bernstein 上调 Arrowhead 目标价</li>
<li>中性情绪：HC Wainwright 对几个季度的每股收益预估仅进行了小幅修订，有些季度略低，有些季度略高，表明 Arrowhead 的管线驱动盈利路径整体论点没有重大变化。HC Wainwright 估计修订</li>
<li>中性情绪：最近的报道还强调了 Arrowhead 正在进行的估值辩论和即将公布的临床结果，这可能在关键催化剂之前保持了投资者的兴趣。2026 年下半年多个重要临床结果</li>
<li>消极情绪：HC Wainwright 下调了 Arrowhead 的几个短期盈利预测，包括 2026 年第三季度、2027 年第一季度和 2027 年第二季度，这反映了对持续亏损的预期，直到最终改善。Arrowhead 短期盈利估计下调</li>
</ul>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Arrowhead Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于 RNA 干扰 (RNAi) 治疗药物的发现、开发和商业化。自 2008 年成立以来，Arrowhead 利用其专有的递送平台——内部称为先进 RNAi 化合物 (ARC) 技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久的、针对性的治疗，涵盖多个治疗领域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的管线包括多个处于不同开发阶段的候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Arrowhead Pharmaceuticals</li>
<li>YETI 在盈利超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度盈利后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Arrowhead Pharmaceuticals 吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arrowhead Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而 Arrowhead Pharmaceuticals 并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arrowhead Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock

Market Beat

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

美国制药 ETF - iShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做空 - Direxion

医疗业 ETF - Vanguard

Bank of Nova Scottia

摩根大通

加拿大皇家银行

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

内幕交易：ArrowHead Pharma（NASDAQ:ARWR）的董事出售了 2,970 股股票